Mineralys spikes as blood pressure drug undergoes FDA review
Source: SeekingAlpha
2026-03-10 13:03:17 ET
More on Mineralys Therapeutics
- Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026
- Seeking Alpha’s Quant Rating on Mineralys Therapeutics
- Historical earnings data for Mineralys Therapeutics
- Financial information for Mineralys Therapeutics
Read the full article on Seeking Alpha
For further details see:
Mineralys spikes as blood pressure drug undergoes FDA review
Mineralys Therapeutics Inc.
NASDAQ: MLYS
MLYS Trading
10.1% G/L:
$29.21 Last:
2,103,006 Volume:
$26.45 Open:
MLYS Latest News
March 09, 2026 04:30:00 pm
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
MLYS Stock Data
$2,458,878,433
58,911,783
0.83%
65
N/A
Biotechnology & Life Sciences
Healthcare
US
Radnor
